


MSCI USA IMI Genomic Innovation Select 50 Index (USD)

The MSCI USA IMI Genomic Innovation Select 50 Index is based on the MSCI USA IMI Index, its parent index, and includes large, mid and small-cap securities of the U.S equity markets. The Index aims to represent the performance of a set of companies that are expected to derive significant revenues, based on the underlying index methodology criteria, from the development of new products and services in the field of genomic sequencing, synthesis, analysis or instrumentation, enable bio computing, bioinformatics, molecular diagnostics and agricultural biotechnology.

For a complete description of the index methodology, please see [Index methodology - MSCI](#).

CUMULATIVE INDEX PERFORMANCE – NET RETURNS (USD) (NOV 2016 – MAR 2024)



ANNUAL PERFORMANCE (%)

Year	MSCI USA IMI Genomic Innovation Select 50	MSCI USA IMI
2023	0.46	25.64
2022	-31.36	-19.61
2021	2.44	25.62
2020	46.58	20.46
2019	36.48	30.39
2018	-10.32	-5.72
2017	34.08	20.59

INDEX PERFORMANCE – NET RETURNS (%) (MAR 29, 2024)

	1 Mo	3 Mo	1 Yr	YTD	ANNUALIZED				Since Nov 30, 2016	FUNDAMENTALS (MAR 29, 2024)			
					3 Yr	5 Yr	10 Yr			Div Yld (%)	P/E	P/E Fwd	P/BV
MSCI USA IMI Genomic Innovation Select 50	0.89	2.52	1.79	2.52	-9.49	3.06	na	7.21		0.61	10,000.00	54.70	4.28
MSCI USA IMI	3.21	9.84	28.72	9.84	9.49	13.94	na	13.53		1.37	26.57	21.30	4.37

INDEX RISK AND RETURN CHARACTERISTICS (NOV 30, 2016 – MAR 29, 2024)

	Beta	Tracking Error (%)	Turnover (%) ¹	ANNUALIZED STD DEV (%) ²			SHARPE RATIO ^{2,3}			Since Nov 30, 2016	MAXIMUM DRAWDOWN		
				3 Yr	5 Yr	10 Yr	3 Yr	5 Yr	10 Yr		(%)	Period YYYY-MM-DD	
MSCI USA IMI Genomic Innovation Select 50	1.03	15.44	26.98	23.65	24.02	na	-0.41	0.16	na	0.33	53.02	2021-09-09–2023-10-30	
MSCI USA IMI	1.00	0.00	1.97	17.89	18.97	na	0.45	0.68	na	0.72	35.04	2020-02-19–2020-03-23	

¹ Last 12 months

² Based on monthly net returns data

³ Based on NY FED Overnight SOFR from Sep 1 2021 & on ICE LIBOR 1M prior that date

MSCI USA IMI Genomic Innovation Select 50 Index (USD)

INDEX CHARACTERISTICS

	MSCI USA IMI Genomic Innovation Select 50	MSCI USA IMI
Number of Constituents	48	2,378
	Weight (%)	
Largest	6.13	5.86
Smallest	0.17	0.00
Average	2.08	0.04
Median	1.15	0.01

TOP 10 CONSTITUENTS

	Index Wt. (%)	Parent Index Wt. (%)
ILLUMINA	6.13	0.04
MODERNA	5.88	0.07
AGILENT TECHNOLOGIES	5.57	0.08
THERMO FISHER SCIENTIFIC	5.40	0.44
REGENERON PHARMACEUTICAL	5.24	0.20
DANAHER CORP	5.16	0.35
VERTEX PHARMACEUTICALS	5.11	0.21
IQVIA HOLDINGS	5.04	0.09
ABBOTT LABORATORIES	4.90	0.39
BRISTOL-MYERS SQUIBB CO	4.84	0.22
Total	53.27	2.10

The MSCI USA IMI Genomic Innovation Select 50 Index was launched on Jan 22, 2021. Data prior to the launch date is back-tested test (i.e. calculations of how the index might have performed over that time period had the index existed). There are frequently material differences between back-tested performance and actual results. Past performance – whether actual or back-tested – is no indication or guarantee of future performance.

ABOUT MSCI

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 45 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com.

The information contained herein (the "Information") may not be reproduced or disseminated in whole or in part without prior written permission from MSCI. The Information may not be used to verify or correct other data, to create indexes, risk models, or analytics, or in connection with issuing, offering, sponsoring, managing or marketing any securities, portfolios, financial products or other investment vehicles. Historical data and analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information or MSCI index or other product or service constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy. Further, none of the Information or any MSCI index is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR ITS OR THEIR DIRECT OR INDIRECT SUPPLIERS OR ANY THIRD PARTY INVOLVED IN THE MAKING OR COMPILING OF THE INFORMATION (EACH, AN "MSCI PARTY") MAKES ANY WARRANTIES OR REPRESENTATIONS AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH MSCI PARTY HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING ANY OF THE FOREGOING AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL ANY OF THE MSCI PARTIES HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL (INCLUDING LOST PROFITS) OR ANY OTHER DAMAGES EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited.

© 2024 MSCI Inc. All rights reserved.

